Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369710 | 0.90 | CA2 (0.44) | CA2CA9DRD2DRD1KDM4E | |
| SCHEMBL10696554 | 0.86 | FYN (0.42) | CA2CA9DRD2DRD1KDM4E | |
| SCHEMBL3506070 | 0.85 | CA2 (0.67) | CA2CA9DRD2DRD1KDM4E | |
| SCHEMBL9885510 | 0.81 | DRD2 (0.42) | DRD2DRD1KDM4ETDP1GAA | |
| SCHEMBL27624983 | 0.81 | ABCB1 (0.68) | DRD2DRD1DHCR7ABCB1 | |
| SCHEMBL27624937 | 0.80 | COMT (0.46) | CA2CA9KDM4ETDP1GAA | |
| SCHEMBL27624778 | 0.80 | ABCB1 (0.67) | DRD2DRD1DHCR7ABCB1 | |
| SCHEMBL27644910 | 0.80 | ABCB1 (0.67) | DRD2DRD1DHCR7ABCB1 | |
| SCHEMBL27624812 | 0.80 | ABCB1 (0.67) | DRD2DRD1DHCR7ABCB1 | |
| SCHEMBL27624961 | 0.80 | ABCB1 (0.67) | DRD2DRD1DHCR7ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019070973-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019070973-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
| EP-2268280-B1 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8173672-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173672-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009117283-A2 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | CA2 3273/4885CA9 4588/4885DRD2 230/4885 |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | PGLS, GNE, COMT | CA2 2838/4885CA9 2535/4885DRD2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.